ESMO 2021 Lung Cancer – Robin Cornelissen
Robin Cornelissen discusses new agents developed for the treatment of NSCLC patients with EGFR or HER2 exon 20 insertion mutations, the role of next-generation sequencing in clinical practice, rare drivers of lung cancer with potential interest in the future, targeted approaches in the management of lung cancer as well as prognostic markers for survival or clinical decision making before extended pleurectomy and decortication surgery in malignant pleural mesothelioma.
Here is the full ESMO 2021 Lung Cancer report.
More posts
Expansion of treatments and insights in the early-stage disease setting
The management of patients with stage I-III non–small-cell lung cancer (NSCLC) is still characterized by a high unmet medical need as up to 60 % experience disease relapse despite treatment with curative intent [1]. IMpower010 was the first phase III study of cancer immunotherapy to demonstrate a disease-free survival (DFS) benefit in the adjuvant situation after complete resection and platinum-based chemotherapy.
Preface
With the World Conference on Lung Cancer that took place on 8th–14th September 2021 and the ESMO Congress on 16th–21st September, two prestigious cancer congresses have offered a wealth of new preclinical and clinical information in the field of lung cancer. Results from pivotal studies were updated, and fascinating novel treatment approaches were presented to large audiences around the world.
